Verrica Pharmaceuticals Inc. (VRCA): R&D Expense
$8.86M
Year ended 2025-12-31
$14.62M
Trailing 12 months to 2026-06-30
-10.1%
3-year compound annual growth
-10.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.86M | -25.2% | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $11.84M | -41.7% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $20.30M | +66.4% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $12.20M | -23.4% | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | $15.93M | +1.6% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $15.67M | +1.5% | 2022-03-02, From 2020-01-01 |
| 2019-12-31 | $15.44M | +20.3% | 2021-03-17, From 2019-01-01 |
| 2018-12-31 | $12.83M | +243.9% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $3.73M | n/a | 2019-03-07, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $8.86M | -25.2% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $604.3K | -35.3% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $672.7K | -50.6% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $7.17M | -1.4% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $114.60M | +40.9% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $85.47M | -9.6% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $3.72M | +78.0% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $182.78M | +14.5% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $56.04M | +36.0% |
Compare VRCA, SBFM, BGM, ZOMDF side by side · Screen every company in Pharmaceutical Preparations ↗